Anaplastic Lymphoma Clinical Trial
— LEUK-ALCLOfficial title:
Leukemic Phase of ALK+ Anaplastic Lymphoma in Real-life Practice: Experience of a University Clinical Hematology Laboratory
NCT number | NCT04908059 |
Other study ID # | 8115 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 27, 2021 |
Est. completion date | July 13, 2021 |
Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL
Status | Recruiting |
Enrollment | 2 |
Est. completion date | July 13, 2021 |
Est. primary completion date | July 13, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 9 Years and older |
Eligibility | Inclusion Criteria: - Patients presenting a leukemic phase of anaplastic lymphoma Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
France | Hematology Laboratory - Strasbourg University Hospitals | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | A retrospective study of the diagnostic description of the leukemic phases of anaplastic lymphoma in real life | Files analysed retrospectively from January 01, 2020 to December 31, 2020 will be examined] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03971305 -
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
|
||
Suspended |
NCT04828174 -
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
|
Phase 1 |